• Blog
  • Overactive Bladder (OAB) Therapeutics Market Growth Analysis

    Overactive Bladder (OAB) Therapeutics Market Growth Analysis

    Overactive Bladder (OAB) Therapeutics Market Growth Analysis
    Report code - SR1429 Delivery - 2 Weeks
    Overactive Bladder (OAB) Therapeutics Market Growth, Trends, Dynamics & Market Insight See more...

    Market Insights

    The Overactive Bladder (OAB) Therapeutics Market is estimated to grow from USD 3.6 billion in 2020 to USD 4.3 billion by 2026 at a healthy CAGR of 3.0% during the forecast period.

    Wish to get a free sample? Register Here

    What is overactive bladder?

    Overactive bladder (OAB) may be a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency. The common symptoms of OAB include high urinary frequency, urgency, and urinary incontinence. These drugs act by antagonizing cholinergic receptors that provide relief from frequent urination. 

    Key Players

    Key players operating in the Overactive Bladder (OAB) Therapeutics market are-

    • Allergan PLC (US)
    • Astellas Pharma Inc. (Japan)
    • Cogentix Medical Inc. (US)
    • Endo International PLC (Ireland)
    • Hisamitsu Pharmaceutical Co. Inc. (Japan)
    • Johnson & Johnson (US)
    • Medtronic PLC (Ireland)
    • Pfizer Inc. (US)
    • Sanofi (France)
    • Teva Pharmaceutical Industries Limited (Israel).

    Market Dynamics

    Growing incidence of diseases, such as Parkinson’s disease, which leads to overactive bladder disorder, and the rising geriatric population, are key factors propelling the market growth. Urinary incontinence generally rises with aging. OAB has a major negative impact on the quality of life and health of the aged population. With the rising burden of OAB, coupled with other urinary diseases, the growth of the overactive bladder treatment market is expected to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceutical companies, are anticipated to offer lucrative growth opportunities.

    COVID-19 Impact

    The COVID-19 outbreak has moderately affected the Overactive Bladder (OAB) Therapeutics industry. The virus outbreak has turned the lives of people worldwide, with the number of cases increasing rapidly. The COVID-19 crisis has reduced the number of visits to hospitals and postponement of urology to curb the spread of the virus, thus affecting market growth amid the pandemic.

    To get the full scope of the report, Register Here

    Segment Analysis

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    The market is segmented into the following categories-

    By Therapy Type

    • Anticholinergics
    • Mirabegron
    • Neurostimulation
    • Intravesical Instillation
    • Others

    By Disease Type

    • Idiopathic Overactive Bladder
    • Neurogenic Overactive Bladder

    By Region

    • North America
    • Asia-Pacific
    • Europe 
    • Rest of the World

    Therapy Trends

    The overactive bladder (OAB) therapeutics market is classified into anticholinergics, mirabegron, neurostimulation, intravesical installation, and others. The anticholinergics segment held a significant market share in 2020 and is estimated to register a healthy CAGR during the forecast timeline. This is mainly attributed to the high prevalence of overactive bladder. Due to bladder muscle weakness post-pregnancy and menopause, women are more vulnerable to the condition. The growing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period, which bolsters the segment growth. 

    Regional Analysis

    The North American market accounted for a significant share in 2020 and is expected to grow at a substantial CAGR in the following years. This is mainly ascribed to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the rising prevalence of the disease with rising age, and the large presence of major players, the market is likely to boost the market growth. Due to the growing prevalence of bladder over-activity, healthcare expenditure, geriatric population, and awareness about overactive bladder treatments, thereby proliferates the regional market growth.

    To know which region offers the best growth opportunities, Register Here

    Target Audience

    Here is the list of the group of customers that the overactive bladder (OAB) therapeutics market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What deliverables will you get in this report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth analysis of the Overactive Bladder (OAB) Therapeutics Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional and country level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The overactive bladders therapeutics market is expected to witness an impressive growth of 3.0% CAGR in the coming years.

    Allergan PLC (US), Astellas Pharma Inc. (Japan), Cogentix Medical Inc. (US), Endo International PLC (Ireland), Hisamitsu Pharmaceutical Co. Inc. (Japan), Johnson & Johnson (US), Medtronic PLC (Ireland), Pfizer Inc. (US), Sanofi (France), and Teva Pharmaceutical Industries Limited (Israel) are among the key players in the overactive bladders therapeutics market.

    The overactive bladder therapeutics market size is expected to reach USD 4.3 billion in the foreseeable future.

    The anticholinergics segment is expected to register healthy CAGR in the overactive bladders therapeutics market in the coming years.

    North America is expected to grow at a substantial CAGR in the overactive bladders therapeutics market in the next five years.

    Growing incidence of diseases, such as Parkinsons disease, which leads to overactive bladder disorder, and rising geriatric population, are key factors propelling the market growth. Urinary incontinence generally rises with aging. OAB has a major negative impact on the quality of life and health of the aged population. With the rising burden of OAB, coupled with other urinary diseases, the growth of the overactive bladder treatment market is expected to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceutical companies, are anticipated to offer lucrative growth opportunities.